0001415889-24-018256.txt : 20240626 0001415889-24-018256.hdr.sgml : 20240626 20240626172256 ACCESSION NUMBER: 0001415889-24-018256 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240621 FILED AS OF DATE: 20240626 DATE AS OF CHANGE: 20240626 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Quinlan Amy CENTRAL INDEX KEY: 0002027706 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39979 FILM NUMBER: 241074576 MAIL ADDRESS: STREET 1: C/O VOR BIOPHARMA INC. STREET 2: 100 CAMBRIDGEPARK DRIVE, SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vor Biopharma Inc. CENTRAL INDEX KEY: 0001817229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-655-6580 MAIL ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 3 1 form3-06262024_090652.xml X0206 3 2024-06-21 0 0001817229 Vor Biopharma Inc. VOR 0002027706 Quinlan Amy C/O VOR BIOPHARMA INC. 100 CAMBRIDGEPARK DRIVE, SUITE 101 CAMBRIDGE MA 02140 false true false false Vice President of Finance Common Stock 55812 D Employee Stock Option (right to buy) 1.904 2030-08-30 Common Stock 117127 D Employee Stock Option (right to buy) 8.63 2032-01-31 Common Stock 29000 D Employee Stock Option (Right to Buy) 5.55 2033-02-05 Common Stock 22500 D Employee Stock Option (Right to Buy) 2.41 2034-01-28 Common Stock 12500 D Includes 15,000 shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs shall vest in full on September 1, 2024, subject to the Reporting Person's continued service as of each such date. Includes 7,735 shares underlying RSUs. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs shall vest in eleven quarterly installments beginning on August 6, 2024, subject to the Reporting Person's continued service as of each such date. Includes 17,579 shares underlying RSUs. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs shall vest in fifteen quarterly installments beginning on August 1, 2024, subject to the Reporting Person's continued service as of each such date. The original option award was for 122,127 shares. 25% of these options vested on August 28, 2021, and the remainder vest over the following three years in equal monthly installments, subject to the Reporting Person's continuous service through each such vesting date. These options vest over four years in equal monthly installments beginning March 1, 2022, subject to the Reporting Person's continuous service through each such vesting date. These options vest over four years in equal monthly installments beginning March 6, 2023, subject to the Reporting Person's continuous service through each such vesting date. These options vest over four years in equal monthly installments beginning March 1, 2024, subject to the Reporting Person's continuous service through each such vesting date. /s/ Katie Kazem, Attorney-in-Fact 2024-06-26 EX-24 2 ex24-06262024_090655.htm ex24-06262024_090655.htm

POWER OF ATTORNEY


(For Executing Form ID and Forms 3, 4 and 5)


Know all by these presents, that the undersigned hereby constitutes and appoints each of Tania Philipp and Robert Ang of Vor Biopharma Inc. (the "Company") and Div Gupta, Katie Kazem, David Brinton, Angela Kim, Cathy Rude and Jason Minio of Cooley LLP, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:


(1)

Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC"), a Form ID and Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company;


(2)

Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form ID and Forms 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such forms with the SEC and any stock exchange, self-regulatory association or any similar authority; and


(3)

Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.


The undersigned hereby grants to each such attorneyinfact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneyinfact, or such attorneyinfact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.


This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or employed by or a partner at Cooley LLP or another law firm representing the Company, as applicable.  


IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.



Date:  June 18, 2024



/s/ Amy Quinlan

Amy Quinlan